91 (0.78–1.06) Current use 196 2.9 520 2.0 1.52 (1.28–1.80)d,e 1.19 (1.00–1.42)d Duration of usec ≤3 months 47 0.7 104 Crenigacestat in vivo 0.4 1.85 (1.30–2.62) 1.57 (1.10–2.24) 4–12 months 43 0.6 116 0.4 1.51 (1.06–2.15) 1.14 (0.79–1.64) 13–36 months 51 0.8 168 0.6 1.22 (0.89–1.68) 0.92 (0.67–1.28) >36 months 55 0.8 132 0.5
1.64 (1.19–2.25) 1.30 (0.94–1.81) OR odds ratio, CI confidence interval aAdjusted for use of other antacids, average daily dose of oral corticosteroids, anxiolytics/hypnotics, short- or long-acting benzodiazepines, hormone replacement therapy, anticonvulsants, antipsychotics, antidepressants, beta-blockers, antidiabetics, two ore more non-steroidal anti-inflammatory drug dispensings, disease modifying antirheumatic drugs, a history of digestive system disorders, anaemia, mental disorders, cerebrovascular disease, congestive heart failure, endocrine disorders, rheumatoid arthritis, diabetes mellitus, chronic obstructive pulmonary disease and inflammatory bowel disease. Furthermore, the proton pump inhibitor (PPI) analysis
was adjusted for the use of histamine H2-receptor antagonists (H2RAs) and the H2RA analysis for the use of PPIs bWald statistic: current PPI use statistically significantly different (P < 0.05) from learn more recent PPI use cDuration of use: duration of continuous use with washout periods of ≤3 months dWald statistic: current H2RA use statistically significantly different (P < 0.05) from recent H2RA use eWald statistic: current H2RA use statistically significantly different (P < 0.05) from distant H2RA use Fig. 1 Risk of hip/femur fracture and time between index date and most recent dispensing of acid suppressants. Solid lines, solid circles AORs of PPI Duvelisib nmr including confidence bands; dashed lines, open circles H2RAs including confidence bands (adjusted for same confounders as listed under Table 2) Table 2 also shows that longer durations of use attenuated the risk association. Current OSBPL9 PPI users were at highest risk during the first year of continuous exposure, but this risk decreased over time. In addition, no increased risk of hip/femur fracture was observed among current users (8 cases and 29 exposed controls) with a duration of PPI use exceeding 7 years,
yielding an AOR of 0.89 (95% CI 0.34–2.01). The association between the duration of continuous PPI and H2RA use, and the risk of hip fracture is graphically illustrated in Fig. 2. Fig. 2 Risk of hip/femur fracture and continuous duration of PPI or H2RA use among current users. Solid lines, solid circles AORs of PPI including confidence bands; dashed lines, open circles H2RAs including confidence bands (adjusted for same confounders as listed under Table 2) Furthermore, the risk of hip/femur fracture was highest among those current users who received the highest daily dose of PPIs. The PPI use below an average daily dose of 1.00 DDD, resulted in an AOR of 1.21 (95% CI 0.93–1.57) as shown in Table 3. This risk declined to an AOR of 1.12 (95% CI 0.88–1.